Milestone Scientific reports $2.8 million in second-quarter revenue
Key Facts
Milestone Scientific said second-quarter 2026 revenue rose 22% year over year to $2.8 million, with medical segment revenue growing 231% from the same period a year earlier, according to a company statement published via GlobeNewswire on August 14. First-half revenue was $5.0 million, up 10% year over year. Results showed quarterly net loss narrowing to $1.1 million from $1.5 million in the second quarter of 2025. Management also reaffirmed its full-year revenue outlook of $9.8 million to $10.2 million. The company said CompuFlo revenue is positioned to grow at a faster pace than its overall business during the rest of the year.
Quarterly revenue growth came despite management describing the third quarter as seasonally slower, noting that second-quarter revenue benefited from two large international orders that it does not expect to recur in the third quarter. The company said those orders supported second-quarter results, putting the comparison between the two periods in its seasonal context. In the first half, the company recorded total revenue of $5.0 million, up 10% from the corresponding period of 2025. First-half net loss was $1.9 million, compared with a loss of $3.5 million in the first half of the prior year. The narrower loss over the six months represents an improvement from the year-earlier period, while the company remained loss-making.
On quarterly profitability, the loss was $1.1 million, or $0.01 per share, compared with $1.5 million, or $0.02 per share, a year earlier. The first-half loss was $1.9 million, or $0.02 per share, compared with $3.5 million, or $0.04 per share, in the corresponding period of 2025. The comparison shows losses declining on both a quarterly and first-half basis, alongside higher revenue in both periods. As of June 30, 2026, the company had $2.1 million in cash and cash equivalents and working capital of $3.7 million. These balances provide the reported liquidity picture at the end of the first half, alongside continued operating and net losses.
The liquidity position has an older context: in its 2025 annual filing, Milestone Scientific reported an operating loss of $5.7 million and cash and cash equivalents of about $1.1 million at year-end. The company said in the filing that these results raised substantial doubt about its ability to continue as a going concern. Against that cash balance at the end of 2025, the company reported $2.1 million in cash and cash equivalents on June 30, 2026. In August, management maintained its full-year revenue outlook of $9.8 million to $10.2 million. It also expected CompuFlo revenue to grow at a faster pace than overall activity during the remainder of 2026.
The company had scheduled its third-quarter results call for November 13, 2026, at 8:30 a.m. Eastern Time, according to a scheduling notice published on November 11. The date follows management's August warning that the two international orders that supported second-quarter revenue were not expected in the third quarter, which it described as seasonally slower. The new results will therefore be watched for revenue against that seasonal factor and for the trajectory of losses after the first-half improvement from the prior year. The annual revenue outlook announced in August also serves as a reference for the remainder of the year. The available facts do not include third-quarter results or a subsequent update to that outlook.